ライフサイエンスコーパス: peripheral artery disease

1 disease, ischemic stroke, heart failure, and peripheral artery disease).

2 r disease (myocardial infarction, stroke, or peripheral artery disease).

3 ion functional class, wall motion score, and peripheral artery disease).

4 ing 27,395 patients with chronic coronary or peripheral artery disease.

5 tions and many strokes, as well as disabling peripheral artery disease.

6 cholesterolaemia were major risk factors for peripheral artery disease.

7 nd localization in tissue from patients with peripheral artery disease.

8 ergistically increases risk in patients with peripheral artery disease.

9 ediated gene expression in a murine model of peripheral artery disease.

10 eGFR] and albuminuria) with the incidence of peripheral artery disease.

11 disease is a risk factor for lower-extremity peripheral artery disease.

12 potent antiplatelet agent, in patients with peripheral artery disease.

13 t advance in the management of patients with peripheral artery disease.

14 dependently associated with the incidence of peripheral artery disease.

15 artery is common in patients suffering from peripheral artery disease.

16 ction seen in rats with ligated arteries and peripheral artery disease.

17 etailing causes of death among patients with peripheral artery disease.

18 in patients with symptomatic femoropopliteal peripheral artery disease.

19 as nonhealing ulcers or gangrene, related to peripheral artery disease.

20 artery disease, cerebrovascular disease and peripheral artery disease.

21 in skeletal muscle biopsies from humans with peripheral artery disease.

22 he most common presentation of infrainguinal peripheral artery disease.

23 y from chronic hindlimb ischemia, a model of peripheral artery disease.

24 ergic signaling in a cohort of patients with peripheral artery disease.

25 in improving the outcomes for patients with peripheral artery disease.

26 of patients with symptomatic femoropopliteal peripheral artery disease.

27 pliteal lesions in symptomatic patients with peripheral artery disease.

28 athophysiology of the exercise impairment in peripheral artery disease.

29 l tool to investigate the pathophysiology of peripheral artery disease.

30 161 patients with AAA and 168 controls with peripheral artery disease.

31 low in the murine hindlimb ischemia model of peripheral artery disease.

32 to be underused among Medicare patients with peripheral artery disease.

33 nd 2010 to estimate the global prevalence of peripheral artery disease.

34 ding 112,027 participants, of which 9347 had peripheral artery disease.

35 risk for stroke, venous thromboembolism and peripheral artery disease.

36 aseline clinical characteristics, except for peripheral artery disease.

37 re considered as biomarkers for coronary and peripheral artery disease.

38 consumption and increased risk of stroke and peripheral artery disease.

39 b endovascular interventions for symptomatic peripheral artery disease.

40 low blood pressure targets in patients with peripheral artery disease.

41 her hazard for MACE or MALE in patients with peripheral artery disease.

42 risk of amputation alone and in concert with peripheral artery disease.

43 gulant therapy in patients with coronary and peripheral artery disease.

44 e (0.91, 0.82-1.01), and a 32% lower risk of peripheral artery disease (0.68, 0.60-0.78).

45 chronic kidney disease (1.7 [1.7-1.8]), and peripheral artery disease (2.3 [2.3-2.4]).

46 ), persistent or recurrent manifestations of peripheral artery disease (22.2%), cardiac conditions (1

47 tes (41.0%), moderate renal failure (40.2%), peripheral artery disease (33.7%), current smoker (13.8%

48 ), chronic kidney disease 4.4 (4.3-4.6), and peripheral artery disease 6.9 (6.8-7.0).

49 was consistently associated with stroke and peripheral artery disease across the different analyses.

50 es were measured in 226 patients with stable peripheral artery disease admitted for nonurgent invasiv

51 Peripheral artery disease affects >200 million people wo

52 Atherosclerotic peripheral artery disease affects 8% to 12% of Americans

53 Rivaroxaban in peripheral artery disease after revascularization.

54 EUCLID trial (Examining Use of Ticagrelor in Peripheral Artery Disease) aimed to describe the inciden

55 % CI, 3.0-4.6) increased risk of amputation; peripheral artery disease alone conferred a 13.9-fold (9

56 le disparities in stroke, heart failure, and peripheral artery disease among African Americans.

57 g, adjusted HR 5.76 [4.90-6.77] for incident peripheral artery disease and 10.61 [5.70-19.77] for amp

58 ents with chronic coronary artery disease or peripheral artery disease and a history of mild or moder

59 rterial studies investigated lower-extremity peripheral artery disease and acute stroke (35% and 24%,

60 nd organizations to advance the treatment of peripheral artery disease and critical limb ischemia.

61 ents with chronic coronary artery disease or peripheral artery disease and history of heart failure (

62 NPR-C as an innovative approach to treating peripheral artery disease and ischemic cardiovascular di

63 d risk of amputation; and the combination of peripheral artery disease and microvascular disease was

64 to ischemic cardiovascular events, including peripheral artery disease and myocardial infarction, whi

65 om classification over time in patients with peripheral artery disease and the association of changes

66 enase bright (ALDHbr) cells in patients with peripheral artery disease and to explore associated clau

67 nd limb outcomes after revascularization for peripheral artery disease and, in particular, prognosis

68 ilure, valvular disease, venous disease, and peripheral artery disease) and the associated outcomes (

69 therothrombosis in patients with coronary or peripheral artery disease, and (4) the development of in

70 pment of HF, ischemic heart disease, stroke, peripheral artery disease, and chronic kidney disease.

71 onary heart disease, cerebrovascular events, peripheral artery disease, and congestive heart failure.

72 n and other coronary artery disease, stroke, peripheral artery disease, and congestive heart failure;

73 ia for up to 24 hours in the murine model of peripheral artery disease, and doubled muscle perfusion

74 of 5 patients with coronary artery disease, peripheral artery disease, and heart failure.

75 n off-loading, stimulation of wound healing, peripheral artery disease, and infection.

76 b has been shown to decrease angiogenesis in peripheral artery disease, and macrophages were well kno

77 G1/G2 alleles with coronary artery disease, peripheral artery disease, and stroke among black indivi

78 ation, atrial fibrillation, ischemic stroke, peripheral artery disease, and venous thromboembolism.

79 hypertrophy, LV ejection fraction <50%, and peripheral artery disease (ankle-brachial index, <0.90).

80 rce, heart failure, coronary artery disease, peripheral artery disease, antiphospholipid syndrome, an

81 s associated dose-dependently with CAD risk, peripheral artery disease, aortic valve stenosis, heart

82 Patients with peripheral artery disease are at risk of systemic athero

83 neuroischaemic if peripheral neuropathy and peripheral artery disease are both present.

84 , such as myocardial infarction, stroke, and peripheral artery disease, are the leading cause of morb

85 munity-based studies since 1997 that defined peripheral artery disease as an ankle brachial index (AB

86 her heart rate, prior myocardial infarction, peripheral artery disease, Asian race, male sex, and hig

87 ischemia (CLI) is the most advanced stage of peripheral artery disease, associated with significant r

88 ents, we analysed adult participants without peripheral artery disease at baseline at the individual

89 sed 817 084 individuals without a history of peripheral artery disease at baseline from 21 cohorts.

90 professionals and millions of patients with peripheral artery disease at the 2015 Centers for Medica

91 Older age, shorter height, ischemic cause, peripheral artery disease, atrial fibrillation, diabetes

92 anisms underlying the exercise impairment in peripheral artery disease based on an evaluation of the

93 es the first comparison of the prevalence of peripheral artery disease between high-income countries

94 atment of diabetic microvascular disease and peripheral artery disease but are hindered by the comple

95 ascularization of femoropopliteal lesions in peripheral artery disease, but mortality is a safety con

96 lure (HF), atrial fibrillation (AF), stroke, peripheral artery disease, cancer, liver-, rheumatic-, a

97 The Western Pacific Region had the most peripheral artery disease cases (74.08 million), whereas

98 More than two thirds of the global peripheral artery disease cases were concentrated in 15

99 emoral artery of a rat for 72 h, a model for peripheral artery disease, causes an exaggerated exercis

100 Future peripheral artery disease cell therapy investigational t

101 In the peripheral artery disease cohort, the primary end point

102 Peripheral artery disease, common in metabolic syndrome

103 f Major Cardiovascular Events in Coronary or Peripheral Artery Disease [COMPASS]; NCT01776424).

104 Conclusions and Relevance: Peripheral artery disease confers a poor prognosis in pa

105 The percutaneous therapies for peripheral artery disease continue to evolve with longer

106 Percutaneous therapies for peripheral artery disease continue to evolve with new te

107 Peripheral artery disease continues to become an increas

108 cular or Surgical Limb Revascularization for Peripheral Artery Disease) demonstrated superiority of r

109 chronic lung disease, age 75 years or older, peripheral artery disease, diabetes, tobacco use, white

110 red and fifty-five patients with symptomatic peripheral artery disease due to de novo superficial fem

111 diagnoses (coronary artery disease, stroke, peripheral artery disease, dysrhythmias, or heart failur

112 Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease [EUCLID]; NCT01732822).

113 ith chronic kidney disease), and at least 50 peripheral artery disease events, we analysed adult part

114 Approximately one-third of patients with peripheral artery disease experience intermittent claudi

115 May 10, 2016, we enrolled 7470 patients with peripheral artery disease from 558 centres.

116 mates of the prevalence and risk factors for peripheral artery disease globally and regionally and, f

117 ificantly improved stratification of AAA and peripheral artery disease groups when compared with trad

118 lled based on previous revascularization for peripheral artery disease had higher rates of myocardial

119 Peripheral artery disease had to be defined as an ankle-

120 In the 21st century, peripheral artery disease has become a global problem.

121 lar procedures and bleeding in patients with peripheral artery disease has not been well described in

122 Patients with peripheral artery disease have a high risk of future car

123 Patients with peripheral artery disease have a marked reduction in exe

124 Patients with peripheral artery disease have an increased risk of card

125 the past decade, new epidemiological data on peripheral artery disease have emerged, enabling us to p

126 ratio, 1.20 [95% CI, 1.05-1.36; P=0.007) and peripheral artery disease (hazard ratio, 1.15 [95% CI, 1

127 cluding acute myocardial infarction, stroke, peripheral artery disease, heart failure and sudden card

128 uable tool for the treatment of coronary and peripheral artery disease; however, no solution is avail

129 rdial infarction, or stroke in patients with peripheral artery disease; however, vorapaxar significan

130 ER = $44,779/QALY gained), and patients with peripheral artery disease (ICER = $13,427/QALY gained).

131 lobally, 202 million people were living with peripheral artery disease in 2010, 69.7% of them in LMIC

132 ple aged 25 years and older were living with peripheral artery disease in 2015, among whom 72.91% wer

133 pool the odds ratios of 30 risk factors for peripheral artery disease in HICs and LMICs.

134 Overall, the global prevalence of peripheral artery disease in people aged 25 years and ol

135 umber of recommendations for lower extremity peripheral artery disease in the current guideline, decr

136 h for studies reporting on the prevalence of peripheral artery disease in the general population that

137 3.05 ([95% CI, 1.92-4.85] P=2.30x10(-6)) for peripheral artery disease in the inverse variance-weight

138 There are >12 million patients with peripheral artery disease in the United States.

139 C), establishes the primary risk factors for peripheral artery disease in these settings, and estimat

140 eview of the literature on the prevalence of peripheral artery disease in which we searched for commu

141 In patients with symptomatic peripheral artery disease, in comparison with LEB, PVI w

142 ID trial (Examining the Use of Ticagrelor in Peripheral Artery Disease) included 13 885 participants

143 Treatment for symptomatic peripheral artery disease includes lower extremity bypas

144 d dipstick proteinuria with the incidence of peripheral artery disease (including hospitalisation wit

145 ceding decade the number of individuals with peripheral artery disease increased by 28.7% in LMIC and

146 The prevalence of peripheral artery disease increased consistently with ag

147 ncluding hospitalisation with a diagnosis of peripheral artery disease, intermittent claudication, le

148 Peripheral artery disease is a major cardiovascular dise

149 Lower limb peripheral artery disease is a prevalent chronic non-com

150 Peripheral artery disease is common and associated with

151 oral and popliteal arteries in patients with peripheral artery disease is compromised by restenosis a

152 Peripheral artery disease is considered to be a manifest

153 The most severe form of peripheral artery disease is critical limb ischemia (CLI

154 ents demonstrated among patients with stable peripheral artery disease is elevated after revasculariz

155 Lower extremity peripheral artery disease is the third leading cause of

156 n important risk factors, a larger burden of peripheral artery disease is to be expected in the fores

157 mb ischemia (CLI), the most advanced form of peripheral artery disease, is associated with significan

158 amputation in patients with lower-extremity peripheral artery disease (LE PAD) during the study peri

159 diameter is associated with lower-extremity peripheral artery disease (LE-PAD).

160 tical limb ischemia, the most severe form of peripheral artery disease, leads to extensive damage and

161 thelial dysfunction present in patients with peripheral artery disease may be better understood by me

162 lled trial conducted among 212 patients with peripheral artery disease (mean age, 65.5 [SD, 6.2] year

163 ncluded 13 885 participants with symptomatic peripheral artery disease; median follow-up was 30 month

164 Patients with qualifying peripheral artery disease (n=3787) had a history of clau

165 Among patients with symptomatic peripheral artery disease, noncardiovascular causes of d

166 We then used the risk factors to predict peripheral artery disease numbers in eight WHO regions (

167 ry heart disease, stroke, heart failure, and peripheral artery disease) occurred (236 events in subje

168 luting Balloons for Treatment of Symptomatic Peripheral Artery Disease of the Femoropopliteal Artery

169 Eligible patients had a history of peripheral artery disease of the lower extremities (prev

170 balloons (DCBs) for treatment of symptomatic peripheral artery disease of the superficial femoral and

171 mia-reperfusion paradigm in 96 patients with peripheral artery disease of varying severity and 10 hea

172 tent claudication with objective evidence of peripheral artery disease), of the carotid arteries (pre

173 with established coronary artery disease or peripheral artery disease often have diabetes mellitus.

174 regional and national numbers of people with peripheral artery disease on the basis of a risk factor-

175 justed analyses, compared with those without peripheral artery disease or microvascular disease, micr

176 ary artery disease, cerebrovascular disease, peripheral artery disease, or abdominal aortic aneurysm

177 scular disease [prior myocardial infarction, peripheral artery disease, or aortic plaque], age 65-75

178 scular disease [prior myocardial infarction, peripheral artery disease, or aortic plaque], age 65-75

179 nary artery diseases, heart failure, stroke, peripheral artery disease, or CVD-related mortality.

180 myocardial infarction or stroke; the primary peripheral artery disease outcome was major adverse limb

181 ARAS was associated with peripheral artery disease (p = 0.004) and lower high-den

182 than in controls without clinically evident peripheral artery disease (P<0.0001).

183 nto categories of 0-, 1-, 2-, 3- or 4-vessel peripheral artery disease (PAD) (ABI of <=0.9).

184 67, 95% CI, 1.14-2.46, P value = 0.008), and peripheral artery disease (PAD) (OR = 2.35, 95% CI, 1.38

185 cco use is an important preventable cause of peripheral artery disease (PAD) and a major determinant

186 about the prevalence of objectively assessed peripheral artery disease (PAD) and its clinical relevan

187 ssociated with chronic kidney disease (CKD), peripheral artery disease (PAD) and neuropathy.

188 Patients with peripheral artery disease (PAD) are at heightened risk f

189 Patients with peripheral artery disease (PAD) are at heightened risk o

190 Patients with peripheral artery disease (PAD) are at heightened risk o

191 Patients with peripheral artery disease (PAD) are at heightened risk o

192 Patients with peripheral artery disease (PAD) are at risk of major adv

193 New data on the epidemiology of peripheral artery disease (PAD) are available, and they

194 lking ability in people with lower extremity peripheral artery disease (PAD) are unclear.

195 cy and safety of evolocumab in patients with peripheral artery disease (PAD) as well as the effect on

196 Lower extremity peripheral artery disease (PAD) burden differs by race/e

197 ioprotective medications in the treatment of peripheral artery disease (PAD) by socioeconomic status

198 The prevalence of peripheral artery disease (PAD) continues to increase wo

199 with acute coronary syndrome are at risk for peripheral artery disease (PAD) events and venous thromb

200 Peripheral artery disease (PAD) generates tissue ischemi

201 Patients with peripheral artery disease (PAD) have a higher risk of ma

202 Patients with lower-extremity peripheral artery disease (PAD) have greater functional

203 Patients with peripheral artery disease (PAD) have greater incidence o

204 Many patients with peripheral artery disease (PAD) have walking impairment

205 eases related to impaired blood flow such as peripheral artery disease (PAD) impact nearly 10 million

206 To define how the incidence of peripheral artery disease (PAD) in chronic kidney diseas

207 mine whether there is a higher prevalence of peripheral artery disease (PAD) in individuals with lowe

208 se and lifestyle counseling in patients with peripheral artery disease (PAD) in the United States.

209 Peripheral artery disease (PAD) is a leading cause of ca

210 Peripheral artery disease (PAD) is associated with heigh

211 Peripheral artery disease (PAD) is associated with incre

212 Peripheral artery disease (PAD) is associated with incre

213 Peripheral artery disease (PAD) is associated with incre

214 Lower extremity peripheral artery disease (PAD) is frequently underdiagn

215 Peripheral artery disease (PAD) is underrecognized, unde

216 Screening for peripheral artery disease (PAD) may reduce morbidity and

217 reely perfused and ligated femoral arteries: peripheral artery disease (PAD) model.

218 t for claudication that is due to aortoiliac peripheral artery disease (PAD) often relies on stent re

219 ysis patients, but its effect on the risk of peripheral artery disease (PAD) remains unclear.

220 Patients with peripheral artery disease (PAD) show an exaggerated EPR,

221 t evidence to support advising patients with peripheral artery disease (PAD) to participate in a home

222 by screening ankle brachial indices <0.9 for peripheral artery disease (PAD), and ultrasound imaging

223 shown by limb osteoporosis in patients with peripheral artery disease (PAD), but also could result f

224 ndividual clinical risk factors with risk of peripheral artery disease (PAD), but the combined effect

225 variance) to estimate prevalence ratios for peripheral artery disease (PAD), coronary artery calcifi

226 Muscle ischemia, associated with peripheral artery disease (PAD), leads to the release of

227 le of nutrition in the primary prevention of peripheral artery disease (PAD), the third leading cause

228 er Medicaid Expansion (ME) for patients with peripheral artery disease (PAD).

229 r challenge to intraluminal drug delivery in peripheral artery disease (PAD).

230 e 6-minute walk performance in patients with peripheral artery disease (PAD).

231 d improving outcomes in patients with severe peripheral artery disease (PAD).

232 sed revascularization rates in patients with peripheral artery disease (PAD).

233 effective treatment option for patients with peripheral artery disease (PAD).

234 long-term diabetes complications, including peripheral artery disease (PAD).

235 ngiogenic cytokine elevated in patients with peripheral artery disease (PAD).

236 ity among men and women with lower extremity peripheral artery disease (PAD).

237 oB) and lipoprotein (a) [Lp(a)], and risk of peripheral artery disease (PAD).

238 ood pressure (BP) response is exaggerated in peripheral artery disease (PAD).

239 ng is recognized as a strong risk factor for peripheral artery disease (PAD).

240 gerated exercise pressor reflex in rats with peripheral artery disease (PAD).

241 ng ischemia and tissue loss in patients with peripheral artery disease (PAD).

242 l infarction (MI), ischemic stroke (IS), and peripheral artery disease (PAD).

243 ve pulmonary disease (COPD; P=9.3 x 10(-4)), peripheral artery disease (PAD; P=0.090) and abdominal a

244 ion, and lower ankle-brachial index identify peripheral artery disease patients at heightened risk fo

245 Revascularized peripheral artery disease patients face earlier limb and

246 vascularization and amputation procedures in peripheral artery disease patients.

247 ng patients with symptomatic femoropopliteal peripheral artery disease, percutaneous transluminal ang

248 EUCLID trial (Examining Use of Ticagrelor in Peripheral Artery Disease) population, subcategorize amp

249 o be older, female, and have higher rates of peripheral artery disease, prior stroke, and hypertensio

250 inergic signaling plays an important role in peripheral artery disease progression.

251 EUCLID (Examining Use of Ticagrelor in Peripheral Artery Disease) randomized patients with peri

252 this randomized trial in which patients with peripheral artery disease received treatment with paclit

253 d estimates the number of people living with peripheral artery disease regionally and globally.

254 s without subsequent ST in the Excellence in Peripheral Artery Disease registry.

255 anism of adverse limb events associated with peripheral artery disease remains incompletely understoo

256 Peripheral artery disease results in atherosclerotic obs

257 data to support use of these therapies after peripheral artery disease revascularization exist, and m

258 Both eGFR and ACR significantly improved peripheral artery disease risk discrimination beyond tra

259 luminal balloon angioplasty in patients with peripheral artery disease Rutherford-Becker class 2 to 5

260 induced ischemia are highly correlated with peripheral artery disease severity.

261 etinopathy, neuropathy, and nephropathy) and peripheral artery disease status on the risk of incident

262 l Artery Disease Study of 2013 and the China Peripheral Artery Disease Study as sources.

263 We also included the Global Peripheral Artery Disease Study of 2013 and the China Pe

264 tention should be paid to the development of peripheral artery disease symptoms and signs in people w

265 ication is a common and disabling symptom of peripheral artery disease that can be treated with medic

266 Critical limb ischemia is a manifestation of peripheral artery disease that carries significant morta

267 ed trial of 13 885 patients with symptomatic peripheral artery disease that tested the efficacy and s

268 In patients with coronary or peripheral artery disease, the combination of rivaroxaba

269 lasty (PTA) in patients with femoropopliteal peripheral artery disease, the long-term durability of D

270 proving collateral function in patients with peripheral artery disease, there is currently no method

271 In patients with symptomatic peripheral artery disease, ticagrelor was not shown to b

272 d clinical trial that assigned patients with peripheral artery disease to clopidogrel or ticagrelor.

273 associated with 15 putative risk factors for peripheral artery disease to estimate their effect size

274 ndomly assigned 111 patients with aortoiliac peripheral artery disease to receive 1 of 3 treatments:

275 ly assigned 13,885 patients with symptomatic peripheral artery disease to receive monotherapy with ti

276 ants with chronic coronary artery disease or peripheral artery disease to rivaroxaban 2.5 mg twice da

277 ral Artery Disease) randomized patients with peripheral artery disease to ticagrelor versus clopidogr

278 elor In PAD) randomized 13 885 patients with peripheral artery disease to treatment with ticagrelor 9

279 ed increased late mortality in patients with peripheral artery disease treated with PTXDs.

280 Evidence from large, randomized, controlled peripheral artery disease trials reporting long-term out

281 trial enrolled 264 patients with symptomatic peripheral artery disease undergoing percutaneous treatm

282 ard ratios (HRs) for incident study-specific peripheral artery disease was 1.22 (95% CI 1.14-1.30) at

283 the adjusted HR for incident study-specific peripheral artery disease was 1.50 (1.41-1.59) at an ACR

284 Age-specific and sex-specific prevalence of peripheral artery disease was estimated in both high-inc

285 EUCLID (Examining Use of Ticagrelor in Peripheral Artery Disease) was a randomized clinical tri

286 EUCLID trial (Examining Use of Ticagrelor in Peripheral Artery Disease), we examined the changes in R

287 story of stroke, coronary artery disease, or peripheral artery disease were enrolled in a case-contro

288 patients with claudication and infrainguinal peripheral artery disease were randomized at 9 sites, of

289 butable to superficial femoral and popliteal peripheral artery disease were randomly assigned in a 2:

290 18 261 cases of peripheral artery disease were recorded during follow-up

291 ients with stable coronary artery disease or peripheral artery disease were recruited at 602 hospital

292 gina, stroke, transient ischemic attack, and peripheral artery disease, were adjudicated by committee

293 In patients with peripheral artery disease who had undergone lower-extrem

294 In a double-blind trial, patients with peripheral artery disease who had undergone revasculariz

295 Patients with peripheral artery disease who have undergone lower-extre

296 th lower extremity ulcers and a diagnosis of peripheral artery disease who underwent a revascularizat

297 In patients with symptomatic peripheral artery disease with a history of limb revascu

298 uality of life for symptomatic patients with peripheral artery disease with intermittent claudication

299 The treatment of peripheral artery disease with percutaneous transluminal

300 disease conferred increased risk of incident peripheral artery disease, with a strong association bet